Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 12/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 12/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.52 |
| ▸ | MTR | Q99707 | 1/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086964 | 0.87 | SCN1A (0.50) | SCN1ASCN5ASCN9AMTRSSTR5 | |
| SCHEMBL3101936 | 0.87 | SSTR5 (0.50) | SCN1ASCN5ASCN9AMTRSSTR5 | |
| SCHEMBL3090041 | 0.87 | SCN1A (0.50) | SCN1ASCN5ASCN9ASSTR5 | |
| SCHEMBL6191353 | 0.79 | MTR (0.66) | SCN1ASCN5ASCN9AMTR | |
| SCHEMBL3089987 | 0.78 | SCN1A (0.55) | SCN1ASCN5ASCN9AMTRSSTR5 | |
| SCHEMBL9762133 | 0.77 | SCN1A (0.67) | SCN1ASCN5ASCN9AMTR | |
| SCHEMBL27770088 | 0.77 | SSTR5 (0.46) | SSTR5 | |
| SCHEMBL3101560 | 0.76 | SCN1A (0.47) | SCN1ASCN5ASCN9ASSTR5 | |
| SCHEMBL3104473 | 0.76 | SSTR5 (0.48) | SCN1ASCN5ASCN9ASSTR5 | |
| SCHEMBL31633003 | 0.72 | MTR (0.46) | SCN1ASCN5ASCN9AMTRNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | claimed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | claimed |
| EP-2142528-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | claimed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | claimed |
| US-7799806-B2 | Substituted n-benzyl piperidines as somatostatin receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2142528-B1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | HOFFMANN LA ROCHE (CH) | 2010-07-07 | — | — | EP | disclosed |
| EP-2142528-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008122510-A1 | 1-(1-BENZYLPIPERIDIN-4-YL)BENZIMIDAZ0LE -5-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES MELLITUS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249101-A1 | BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES | SSTR5, SSTR3, SSTR1 | SCN1A 1682/4885SCN5A 399/4885SCN9A 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.